Segment Information, EBITDA, Reconciling Items (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020		Mar. 31, 2019
Unallocated costs [Abstract]
Impairment Charges And Gain Loss On Sale Of Assets		$ (0.6)	$ 0.1	$ (2.1)		$ (2.7)
Stock-based compensation		8.6	6.6	35.5		24.1
Restructuring And Other Special Items		8.9	16.1	28.6	[1]	35.2	[1]
Other income/(expense),net	[2]	(36.7)	3.2	(37.2)		(3.9)
Non Allocated Corporate Costs Net		9.1	6.6	31.2		29.3
Segment Reporting Information Unallocated Expense	[3]	$ 63.9	$ 26.0	$ 134.6		$ 95.2

[1] Restructuring and other special items during the nine months ended March 31, 2020 include transaction and integration costs associated with the Company’s gene and cell therapy acquisitions, the disposal of one of its sites in Australia, and other restructuring initiatives across the Company's network of sites. Restructuring and other special items during the nine months ended March 31, 2019 include transaction and integration costs associated with the acquisitions of Catalent Indiana LLC and Juniper Pharmaceuticals, Inc.

[2] Refer to Note 8, Other (income)/expense, net, for details of financing charges and foreign currency translation adjustments recorded within other income/(expense), net.

[3] Unallocated costs include restructuring and special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: